Please assess the completion status of the following clinical trial:

Trial Title: Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* Aged from 18 to 45 (inclusive) at screening~* Body mass index (BMI) from 18.0 to 28.0 kg/m2 (inclusive) at screening~* Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests~Exclusion Criteria:~* Any contraindication to the study drug formulations~* History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs~* Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Intravenous selexipag (Pilot phase) (Type: EXPERIMENTAL): Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
- Sequence A-B (Main phase) (Type: EXPERIMENTAL): Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
- Sequence B-A (Main phase) (Type: EXPERIMENTAL): Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).